Evaluation of the prognostic value of metabolic biomarkers in thyroid cancer

Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/152376

COMPARTIR / EXPORTAR:

SHARE BASE	Comparte tu historia de Acceso Abierto
Visualizar otros formatos: MARC \| Dublin Core \| RDF \| ORE \| MODS \| METS \| DIDL \| DATACITE
Refman EndNote Bibtex RefWorks Excel CSV PDF DataCite Send via email

Campo DC	Valor	Lengua/Idioma
dc.contributor.author	Prieto, Ignacio	-
dc.contributor.author	Sánchez-Ramos, Cristina	-
dc.contributor.author	Monsalve, María	-
dc.date.accessioned	2017-07-05T10:49:56Z	-
dc.date.available	2017-07-05T10:49:56Z	-
dc.date.issued	2016	-
dc.identifier.citation	RICE 2016	-
dc.identifier.uri	http://hdl.handle.net/10261/152376	-
dc.description	Resumen del trabajo presentado a la Reunión Ibérica de Cirugía Endocrina (RICE), celebrada el 5 y 6 de febrero de 2016 en Lisboa (Portugal).-- et al.	-
dc.description.abstract	Thyroid cancer is the most common form of neoplasia of the endocrine system accounting for about 1-3% of all cancers, and its annual incidence has duplicated in last decades. This increase has been associated with diagnostic approach improvements, however many studies support that increased prevalence of some risk factors can also play a role, in particular, the increased number of people with Metabolic Syndrome, defined by the presence of at least three out of five dysmetabolic traits: abdominal obesity, hypertension, low plasma HDL-cholesterol, high plasma glucose and hypertriglyceridemia. To evaluate how alterations in metabolic control were related to thyroid tumor development we analyzed bioenergetic biomarkers in peripheral blood mononuclear cells (PBMCs) and in tumor tissue in a cohort of 32 cancer patients where tumor aggressiveness was evaluated testing for cell proliferation, development of tumor angiogenesis and loss of tissue structure. The results showed that PBMCs of blood samples of patients with carcinoma compared to patients with hyperplasia seemed to have an elevated metabolic activity, increased levels of oxidative phosphorylation biomarkers (PGC-1α), glycolysis biomarkers (PFKB3), and metabolic stress biomarkers, suggesting that tumor development correlates with metabolic activation in leukocytes. To test this idea, patients were divided in two groups based on their PBMCs Prx3 levels and we found that elevated Prx3 correlated with a poorer tissular structure, more active proliferation, and increased glycolytic profile in tumor (evaluated as increased P-AKT membrane levels and punctuated mitochondrial pattern). Therefore, we conclude that elevated Prx3 levels in PBMCs could be a useful prognosis factor for thyroid cancer development.	-
dc.rights	closedAccess	-
dc.title	Evaluation of the prognostic value of metabolic biomarkers in thyroid cancer	-
dc.type	comunicación de congreso	-
dc.date.updated	2017-07-05T10:49:56Z	-
dc.description.version	Peer Reviewed	-
dc.language.rfc3066	eng	-
dc.relation.csic	Sí	-
dc.type.coar	http://purl.org/coar/resource_type/c_5794	es_ES
item.openairetype	comunicación de congreso	-
item.grantfulltext	none	-
item.cerifentitytype	Publications	-
item.openairecristype	http://purl.org/coar/resource_type/c_18cf	-
item.fulltext	No Fulltext	-
Aparece en las colecciones:	(IIBM) Comunicaciones congresos